Articles tagged with Blood Cancer
Four new OICR-funded studies using CATALYST will advance cancer insights by reanalyzing existing patient samples and data. The initiatives aim to improve cancer detection, diagnosis, and treatment by building on previous research.
Researchers at Winship Cancer Institute have administered the first investigational in vivo CAR-T cell therapy in the US for relapsed and refractory multiple myeloma, marking a significant milestone in next-generation cellular therapies. The therapy aims to streamline treatment processes and eliminate delays in care.
A pilot study suggests that physical exercise can support stem cell donation by releasing specific types of blood stem cells into the bloodstream. The exercise stimulus increases stem cell numbers only moderately, but may offer a more targeted approach than medication.
A study finds that a specific subtype of diffuse large B cell lymphoma is dramatically more lethal in women due to genetic differences, and identifies IRAK inhibitors as a potential treatment. The research challenges decades of assumptions about blood cancer and highlights the importance of considering biological sex in cancer trials.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A new study found that targeted maternal screening can prevent adult T-cell leukemia/lymphoma, a rare and aggressive cancer caused by human T-cell leukemia virus type 1. The research identified high disease rates among non-Hispanic Caribbean-born US residents, particularly in Florida and New York.
Researchers developed a novel disease classification system and AI-assisted decision support tool to improve CMML care. The International CMML Prognostic Scoring System (iCPSS) demonstrates superior prognostic discrimination, stratifying patients into five risk groups with different survival outcomes.
A new study found a clear shift in mortality trends in multiple myeloma closely parallels major therapeutic advances. Targeted therapies, including immunomodulatory drugs and CAR T-cell therapies, have significantly improved disease control and induced deep responses.
A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.
A new analysis by researchers at the University of Texas MD Anderson Cancer Center demonstrates that combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) delivers strong long-term outcomes for patients with CBF-AML. The five-year overall survival rate reached 74%...
Researchers have identified a single genetic change that drives the development of myeloid leukaemia in children with Down Syndrome. The study reveals a common vulnerability and treatment target, suggesting potential repurposed treatments. The genetic change, related to the GATA1 gene, is present at all stages of the disease.
Researchers discover cancer-driving genes in microglia of Alzheimer's patients, suggesting a link between blood cancers and the neurodegenerative disease. The findings could lead to new diagnostic tools and therapeutic options for Alzheimer's.
Researchers tracked 30 patients with chronic blood cancers over time, finding that those whose disease remained stable had 'steady' blood cells without additional mutations. Conversely, those with progressing diseases developed changes in DNA years before symptoms worsened. This challenges current views on diagnosing patients without t...
The study projects that cancer rates in Canada will be high in 2026, with declines seen in some cancers like colorectal and leukemia. However, death rates from pancreatic cancer are increasing.
Dr. Ulrich Steidl, MD, Ph.D., has been appointed as the director of the prestigious Montefiore Einstein Comprehensive Cancer Center and vice president of cancer medicine at Montefiore Einstein. With extensive experience in blood cancer and stem cell research, Dr. Steidl aims to advance innovative science that improves lives worldwide.
The ASH HematOmics Program platform combines genomics, gene expression, and clinical information from nearly 6,000 patients with blood cancers. Researchers can explore these datasets together in a single open resource, accelerating discovery in hematological malignancies.
The University of Colorado Anschutz Gates Institute has achieved first-in-U.S. FDA clearance for a novel CAR T-cell therapy targeting aggressive leukemia cells, representing a potential new treatment approach for patients with hard-to-treat disease. The therapy will be evaluated in a Phase 1 clinical trial starting this summer.
Researchers used machine learning methods to identify safe time windows for outpatient stem cell therapy in multiple myeloma patients. The study found that this approach can predict adverse events and enable more precise risk assessment.
Researchers developed an interpretable machine learning algorithm, scOMM, to classify cell types consistently across different single-cell methods. The integration strategies and scOMM establish a robust approach for cell atlas generation in complex tissues, leading to the discovery of previously undetected rare cell types.
The Josep Carreras Leukaemia Research Institute is joining forces with the Chinese Institute of Hematology and Blood Diseases Hospital to advance blood cancer research. The partnership aims to develop joint translational research programmes and accelerate the development of curative therapies for patients with blood cancers.
Researchers developed a laboratory mouse model closely mirroring TCF3::HLF-positive B-ALL and found an inflammatory feedback loop linking leukemia progression and bone destruction. Blocking IL-1β action slowed leukemia growth and reduced bone damage, suggesting new cancer treatments.
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
A minimally invasive liquid biopsy test has been shown to diagnose Burkitt lymphoma rapidly and accurately in sub-Saharan Africa, where delays in traditional testing often prove fatal. The test achieved an overall accuracy of 98% and reduced the time needed to reach a diagnosis by 40 days on average.
Researchers at Albert Einstein College of Medicine have developed a new strategy to engineer immune cells that prolong their effectiveness, addressing a major limitation of current treatments. The new method generates longer-lasting immune cells that provide more sustained control of human blood cancers and suppression of HIV-infection.
A new study found that bilingual consent forms significantly improve cancer treatment understanding among people with limited English, with understanding rising from 35% to 60%. The study, published in Supportive Care in Cancer, examined the impact of different translation approaches on cancer treatment understanding among Bengali- and...
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Researchers developed a biomimetic platform to enhance CAR T cell therapy against leukemia by creating a molecular bridge that reinforces the interface between CAR T cells and leukemia cells. This platform, called FACE, uses ferritin to bind to CD71 on leukemia cells, improving cell recognition and elimination.
Researchers from Dresden University Medicine developed a new treatment approach for relapsed acute myeloid leukemia (AML), combining standard therapy with the BCL2 inhibitor venetoclax. The innovative combination therapy has shown promising efficacy, increasing remission rates to 75% and improving patients' chances of recovery.
A new analysis shows that 42% of treated patients were functionally cured, marking a game-changer for an incurable disease. Recurrence rates declined drastically over time, from 6.8% in the first five years to 0.6% between 15 and 20 years.
A multi-institutional effort aims to refine relapse prediction by identifying genetic markers in blood samples from patients with rare blood cancer. Analyzing blood samples from 190 patients, researchers found that tiny traces of persistent NPM1 mutation were linked to worse outcomes and lower survival rates.
Researchers at Sylvester Cancer Institute have identified a potential workaround for chemotherapy resistance by blocking a key protein. The study aims to teach lymphoma patients practical tools to manage stress and improve their daily quality of life through the SMART 3RP Lymphoma study. Meanwhile, the institute is expanding cancer dis...
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
A global study found that ropeginterferon alfa-2b controls essential thrombocythemia effectively, improves symptoms and reduces serious complications in patients who can't use hydroxyurea. The therapy is expected to be approved for treatment of high-risk blood cancer.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
New studies from Sylvester reveal that 40% of cancers are preventable and that lifestyle interventions can play a crucial role in cancer treatment. Researchers also discovered PFAS on firefighter gear, which may limit exposure to hazardous chemicals linked to cancer.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
CORAL accurately predicts genetic subtypes and patient outcomes in multiple myeloma without costly genomic tests. The technology could be applied to other cancers, opening the door to personalized, faster and widely accessible cancer care.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
A new study by University of Maryland researchers found that Black patients with aggressive leukemia have lower survival rates and are more likely to die from the disease compared to white patients. The disparity is attributed to younger age at diagnosis rather than genetic differences, according to Dr. Shella Saint Fleur-Lominy.
Dr Aldona Mzyk's project uses quantum sensors to track how immune cells interact with tumours, enabling the development of improved patient-tailored cancer therapies and earlier diagnosis tools. The research aims to overcome current cancer immunotherapies' failure in solid tumours by controlling metabolic changes.
Researchers have found that CAR T-cell therapy with cilta-cel leads to higher rates of complete remission and longer progression-free survival compared to ide-cel. Treatment success is linked to factors such as tumour burden, T-cell fitness, and systemic inflammation.
A new Mayo Clinic study found that an off-the-shelf dual-antibody therapy generates deep and durable responses in extramedullary multiple myeloma. In a trial of 90 patients, 79% responded to treatment, with nearly two-thirds maintaining disease control at one year.
A study published in JAMA Network Open found that older adults with chronic kidney disease or cerebrovascular disease are at double the risk for developing neuroinvasive West Nile virus infection, which can lead to paralysis and death. The study identified several risk factors, including male sex, immune suppressants, and multiple scle...
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit cancer-driving protein IGF2BP3, slowing leukemia growth and triggering cancer cell death. The discovery could lead to new treatments for leukemia and other hard-to-treat cancers.
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
A new study finds that most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than intensive chemotherapy. The R-CHOP regimen has shown strong four-year survival rates for THRLBCL patients without significant side effects.
A new clinical trial suggests that combining bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for people with aggressive lymphoma. The study found that 90% of patients were in complete remission at day 90, and about 80% remained in remission at one y...
A new computational tool has discovered a previously unknown protein pathway that triggers the death of blood cancer cells when blocked. This finding could lead to new treatments and improved survival rates for patients with aggressive acute myeloid leukaemia (AML).
A new study presented at ASH 2025 suggests that a virtual program focusing on diet and exercise can help reduce the severity of side effects associated with lymphoma treatment. The program, LIFE-L, showed significant improvements in symptoms such as anxiety, depression, pain, fatigue, and constipation among participants.
Researchers have found that patients with blood cancers can safely receive stem cell transplants from mismatched, unrelated donors using a protective regimen. The study's findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
A clinical trial found that linvoseltamab, a bispecific antibody, eliminated 90% of tumor cells in patients with residual disease. The treatment allows patients to bypass high-dose chemotherapy and bone marrow transplants, potentially improving long-term outcomes.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
A new study from Cincinnati Children's reveals how Fanconi anemia disrupts energy pathways and affects glucose metabolism, paving the way for targeted dietary interventions to improve health and reduce cancer risk. The research uses isotope tracing metabolomics to track nutrient metabolism in people with FA.
A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
A recent study found that young donors (18-35 years old) with minor HLA differences can provide better survival rates and outcomes compared to older sibling donors. Additionally, gender and CMV status also play a role in donor selection.
Researchers have developed a system called CytoDiffusion that uses generative AI to study the shape and structure of blood cells. The system can accurately identify normal blood cell appearances and spot unusual or rare cells that may indicate disease, outperforming existing systems in tests.